CL CLGN CollPlant Biotechnologies Ltd Loading... : Investor Sentiment and Bull/Bear Views

The author argues CLGN has a low float and low market cap with huge upside not yet discovered by the market over roughly the next nine months. They note the fully diluted market cap is about $100M while they see potential for $1B+ over time, and they are willing to hold for years from a tech standpoint. The main risk implied is that the thesis depends on the market eventually recognizing the story, with the author open to rethinking and locking gains if needed.

The author argues that prepaid warrants (tranches two and three) could add roughly 224M shares over an existing ~2M share float, creating over 100-fold dilution if commercialization succeeds, while failure to unlock them means commercialization failed. They note the balance sheet won't support the company long enough and question whether management has a funding plan. The author sees buying before these warrants hit the float as taking on heavy commercialization-failure risk with upside capped by float expansion, and suggests the best case for current shareholders is a buyout by a threatened giant. Main risk cited is dilution and minimal cash on hand.

The author maintains that CLGN will raise capital at a much higher price point because the real story, rebranding, and press coverage will gradually come out. This implies upside before dilution becomes a concern. The main risk remains the eventual capital raise, which they expect to be less damaging than feared.